☆ 4.7 Meeting Abstract

CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data

ANNALS OF ONCOLOGY (2021)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 32, Issue -, Pages S30-S30

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2021.03.037

Keywords

-

Categories

Oncology

Funding

  1. Instituto de Salud Carlos III [PI19/01846]
  2. Instituto 299 de Salud Carlos III [PI18/01408]
  3. Breast Cancer Research Foundation
  4. PhD4MD
  5. Fundacio La Marato TV3
  6. RESCUER Horizon 2020 301
  7. Save the Mama
  8. Pas a Pas
  9. Asociacion Cancer de Mama 302 Metastasico
  10. Fundacion Cientifica Asociacion Espanola Contra el Cancer
  11. Fundacion SEOM (SEOM 2018 Grant: Fellowship for Training in 304 Research in Reference Centers)

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.